Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

RM LAW, P.C. is investigating potential claims against the board of directors of Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (NASDAQ: IDRA) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell the Company to BioCryst Pharmaceuticals, Inc.

If you own shares of  Idera and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.  You may also email Mr. Maniskas at rm@maniskas.com.

Under the terms of the agreement, shareholders of Idera will receive 0.20 shares of the new company stock for each share of Idera common stock. On a proforma, fully diluted basis, giving effect to all dilutive stock options, units and warrants, BioCryst stockholders will own 51.6 percent of the stock of the combined company and Idera stockholders will own 48.4 percent.

Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Idera or not acting in the Company’s shareholders’ best interests in connection with the sale process.